405 related articles for article (PubMed ID: 27449260)
1. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
2. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
3. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
4. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.
Reese AC; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
Urology; 2015 Nov; 86(5):991-5. PubMed ID: 26335496
[TBL] [Abstract][Full Text] [Related]
7. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
12. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
13. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
[TBL] [Abstract][Full Text] [Related]
14. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance.
Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK
Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591
[TBL] [Abstract][Full Text] [Related]
16. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
[TBL] [Abstract][Full Text] [Related]
17. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
18. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.
Diniz CP; Landis P; Carter HB; Epstein JI; Mamawala M
J Urol; 2017 Sep; 198(3):608-613. PubMed ID: 28347771
[TBL] [Abstract][Full Text] [Related]
20. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]